Months after recovery from mild Covid-19 – when antibody levels in the blood have declined – immune cells in bone marrow remain ready to pump out new antibodies against the coronavirus, researchers reported on May 24 in Nature. And according to a new U.S. study, young children appear to be significant carriers of more contagious variants of the new coronavirus, such as the ones identified in the UK and in California.

The U.S. Food and Drug Administration approved G1 Therapeutics’ Cosela (trilaciclib) for injection to decrease the damage to the immune system and bone marrow from chemotherapy.

Swiss drugmaker Novartis won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases.

Merck & Co.’s experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in late-stage trial.

At 2015’s New York Comic Con, Area 23 teamed up with Be The Match to launch The Hero Gene Lab, an effort to expand the number of people registered to […]

Incyte Corp said on Wednesday that it would stop a mid-stage study on its combination treatment after it failed to prove to be sufficiently effective to treat metastatic colorectal cancer. […]

U.S. regulators have approved an experimental treatment from Johnson & Johnson that may offer hope to multiple myeloma patients who have run out of other options against the blood cancer. […]

BOSTON, July 22, 2015 /PRNewswire-USNewswire/ — Using large-scale zebrafish drug-screening models, researchers at Boston Children’s Hospital have identified a potent group of chemicals that helps bone marrow transplants engraft or […]